Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Prepaid Assets (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Prepaid Assets for 14 consecutive years, with $9.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets fell 24.98% year-over-year to $9.2 million, compared with a TTM value of $9.2 million through Dec 2025, down 24.98%, and an annual FY2025 reading of $9.2 million, down 24.98% over the prior year.
  • Prepaid Assets was $9.2 million for Q4 2025 at Karyopharm Therapeutics, up from $8.0 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $31.5 million in Q3 2022 and bottomed at $8.0 million in Q3 2025.
  • Average Prepaid Assets over 5 years is $14.9 million, with a median of $13.7 million recorded in 2021.
  • The sharpest move saw Prepaid Assets skyrocketed 210.81% in 2022, then crashed 57.63% in 2023.
  • Year by year, Prepaid Assets stood at $14.0 million in 2021, then soared by 41.19% to $19.8 million in 2022, then tumbled by 40.4% to $11.8 million in 2023, then increased by 3.66% to $12.2 million in 2024, then fell by 24.98% to $9.2 million in 2025.
  • Business Quant data shows Prepaid Assets for KPTI at $9.2 million in Q4 2025, $8.0 million in Q3 2025, and $8.2 million in Q2 2025.